[Pharmacokinetics and clinical studies of fosfomycin in bile duct infections].
Serum and bile levels of fosfomycin sodium (FOM-Na) were evaluated and the pharmacokinetic parameters were estimated in 10 patients with various forms of biliary drainage (PTCD or T-tube). Clinical trials of FOM-Na were also performed in another 11 patients with bile duct infections and the clinical efficacy was estimated. Mean serum level of FOM-Na after drip infusion of 2 g fosfomycin sodium was 145.43 micrograms/ml at 1 hour, meanwhile bile level was 31.49 micrograms/ml at 2 hours. Serum level of FOM-Na was interpreted by the pharmacokinetic analysis after the damping GAUSS-NEWTON method using the one-compartment open model and bile level of FOM-Na by the damping GAUSS-NEWTON method and deconvolution method. Mean Vd was 12.16 L/body and half-time of serum level was 1.75 hours. Lag-time of bile level was 0.9 hour, Tmax 2.01 hours. The clinical efficacy of FOM-Na was determined excellent without any adverse effect. FOM-Na was remarkably effective in 91% of the patients. Hence, the first choice of FOM-Na against bile duct infections could be recommended.
D000368:Aged; D000900:Anti-Bacterial Agents / Q000378:metabolism*; D001646:Bile / Q000032:analysis; D001650:Bile Duct Neoplasms / Q000150:complications; D002761:Cholangitis / Q000097:blood / Q000188:drug therapy*; D002764:Cholecystitis / Q000097:blood / Q000188:drug therapy*; D005260:Female; D005578:Fosfomycin / Q000378:metabolism* / Q000627:therapeutic use; D006801:Humans; D007700:Kinetics; D008297:Male; D008875:Middle Aged
D000900:Anti-Bacterial Agents; D005578:Fosfomycin